I-Mab ADR (NASDAQ:IMAB) has a beta value of 1.07 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $91.65M, closed the recent trade at $1.19 per share which meant it gained $0.08 on the day or 7.21% during that session. The IMAB stock price is -113.45% off its 52-week high price of $2.54 and 16.81% above the 52-week low of $0.99. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.19 million shares traded. The 3-month trading volume is 201.59K shares.
The consensus among analysts is that I-Mab ADR (IMAB) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
I-Mab ADR (NASDAQ:IMAB) trade information
Sporting 7.21% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IMAB stock price touched $1.19 or saw a rise of 9.85%. Year-to-date, I-Mab ADR shares have moved -37.37%, while the 5-day performance has seen it change 9.17%. Over the past 30 days, the shares of I-Mab ADR (NASDAQ:IMAB) have changed -8.46%. Short interest in the company has seen 0.72 million shares shorted with days to cover at 3.21.
I-Mab ADR (IMAB) estimates and forecasts
Figures show that I-Mab ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -35.33% over the past 6 months, with this year growth rate of 78.41%, compared to 17.70% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -18.89% over the past 5 years. Earnings growth for 2024 is a modest 66.34% while over the next 5 years, the company’s earnings are expected to increase by 26.00%.
IMAB Dividends
I-Mab ADR is expected to release its next earnings report on 2023-Aug-17 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
I-Mab ADR (NASDAQ:IMAB)’s Major holders
The top two institutional holders are HHLR ADVISORS, LTD. with over 6.91 million shares worth more than $11.54 million. As of 2024-06-30, HHLR ADVISORS, LTD. held 7.7935% of shares outstanding.
The other major institutional holder is CALIGAN PARTNERS LP, with the holding of over 3.37 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.64 million and represent 3.8067% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are abrdn Healthcare Investors and Invesco ETF Tr-Invesco Golden Dragon China ETF. As of Jun 30, 2024, the former fund manager holds about 0.07% shares in the company for having 53.88 shares of worth $62485.0 while later fund manager owns 53.13 shares of worth $61613.0 as of Aug 31, 2024, which makes it owner of about 0.07% of company’s outstanding stock.
